Speech-Language Pathologists in Etna, OH Accepting Medicare
3 Speech-Language Pathologists found. Showing 1 - 3
 Megan Lewis, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8500 Columbia Rd Sw, Etna, OH 43062 Phone: 740-927-5906 |
Kayla Williams Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10466 Taylor Rd Sw, Etna, OH 43068 Phone: 614-501-5500 |
Stacey Heldman Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 927b South St., Etna, OH 43062 Phone: 614-746-9724 |
News Archive
Doctors delay talking about end-of-life care
A study published this month finds doctors delay talking about end-of-life care, which often proves very costly. The Los Angeles Times reports: "Most doctors don't talk about end-of-life issues with their cancer patients when those patients are feeling well, a new survey has found." Physicians also tended to delay these conversations "until treatments have been exhausted. Those delays mean patients might not be able to make truly informed choices early in their treatment.
Adoption of hourly rounds schedules for nurses may improve patient safety and satisfaction
Adoption of hourly rounds schedules for nurses working in acute care hospitals may improve patient safety and overall satisfaction with care provided, according to research reported in the Journal for Healthcare Quality, the peer reviewed publication of the National Association for Healthcare Quality.
IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection
IQ Therapeutics B.V., Groningen, the Netherlands, announced this week that in collaboration with the University of Texas Medical Branch it has obtained outstanding results for the treatment of inhalation anthrax. In a rabbit model up to 100% survival could be achieved with extended time to treatment (48h post infection) with a combination of two specific monoclonal antibodies developed by IQ Therapeutics. This has significant potential for saving lives of infected people who have no immediate access to treatment.
Pfizer announces tasocitinib Phase 2 data for plaque psoriasis
Pfizer Inc. today announced that data from a Phase 2 efficacy and safety study of tasocitinib the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis.
New analysis highlights increasing focus of early-stage clinical trials on rare cancers
The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumor types receive increasing attention, according to new research to be presented during the International Congress on Targeted Anticancer Therapies 2019, taking place from today to 27 February in Paris, France.
› Verified 5 days ago